COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Mohamed (RCT)0.14[0.01-2.21]viral+0/53/5RRCITreatmentControlChoudhury (RCT)0.12[0.03-0.50]death2/30317/303Guenezan (RCT)0.37[0.06-1.63]viral load1212Tau​2 = 0.00; I​2 = 0.0%Early treatment0.15[0.05-0.48]2/32020/32085% improvementSeet (CLUS. RCT)0.55[0.38-0.80]severe case42/73564/619OT​1RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP0.55[0.38-0.80]42/73564/61945% improvementAll studies0.32[0.12-0.81]44/1,05584/93968% improvement4 povidone-iodine COVID-19 studiesc19pvpi.com 5/4/211 OT: comparison with other treatmentTau​2 = 0.37; I​2 = 38.8%; Z = 2.40 (p = 0.0082)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)0.12[0.03-0.50]2/30317/303RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment0.12[0.03-0.50]2/30317/30388% improvementAll studies0.12[0.03-0.50]2/30317/30388% improvement1 povidone-iodine COVID-19 mortality resultc19pvpi.com 5/4/21Tau​2 = 0.00; I​2 = 0.0%; Z = 2.88 (p = 0.002)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)0.14[0.03-0.62]2/30314/303RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment0.14[0.03-0.62]2/30314/30386% improvementAll studies0.14[0.03-0.62]2/30314/30386% improvement1 povidone-iodine COVID-19 hospitalization resultc19pvpi.com 5/4/21Tau​2 = 0.00; I​2 = 0.0%; Z = 2.59 (p = 0.0048)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Seet (CLUS. RCT)0.69[0.37-1.01]338/735433/619OT​1RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP0.69[0.37-1.01]338/735433/61931% improvementAll studies0.69[0.63-0.76]338/735433/61931% improvement1 povidone-iodine COVID-19 case resultc19pvpi.com 5/4/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 7.77 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)0.12[0.03-0.50]death2/30317/303RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment0.12[0.03-0.50]2/30317/30388% improvementSeet (CLUS. RCT)0.55[0.38-0.80]severe case42/73564/619OT​1RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP0.55[0.38-0.80]42/73564/61945% improvementAll studies0.30[0.07-1.32]44/1,03881/92270% improvement2 povidone-iodine COVID-19 serious outcomesc19pvpi.com 5/4/211 OT: comparison with other treatmentTau​2 = 0.90; I​2 = 75.4%; Z = 1.59 (p = 0.056)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Mohamed (RCT)0.14[0.01-2.21]viral+0/53/5RRCITreatmentControlChoudhury (RCT)0.12[0.03-0.50]death2/30317/303Choudhury (RCT)0.14[0.03-0.62]hosp.2/30314/303Choudhury (RCT)0.04[0.02-0.07]viral+8/303213/303Guenezan (RCT)0.37[0.06-1.63]viral load1212Seet (CLUS. RCT)0.55[0.38-0.80]severe case42/73564/619OT​1Seet (CLUS. RCT)0.69[0.37-1.01]cases338/735433/619OT​1povidone-iodine COVID-19 outcomesc19pvpi.com 5/4/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to cover all people and all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit